CpG-mediated augmentation of CD8+ T-cell responses in mice is attenuated by a water-in-oil emulsion (Montanide ISA-51) but enhanced by an oil-in-water emulsion (IDRI SE).

about

CpG-mediated augmentation of CD8+ T-cell responses in mice is attenuated by a water-in-oil emulsion (Montanide ISA-51) but enhanced by an oil-in-water emulsion (IDRI SE).

Item

http://www.wikidata.org/entity/Q40724264

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

CpG-mediated augmentation of C ...... l-in-water emulsion (IDRI SE).

@en

type

Item

label

CpG-mediated augmentation of C ...... l-in-water emulsion (IDRI SE).

@en

prefLabel

CpG-mediated augmentation of C ...... l-in-water emulsion (IDRI SE).

@en

P1476

CpG-mediated augmentation of C ...... l-in-water emulsion (IDRI SE).

@en

P2093

Heather L Davis

http://www.w3.org/2001/XMLSchema#string

Qin Zhu

http://www.w3.org/2001/XMLSchema#string

Risini D Weeratna

http://www.w3.org/2001/XMLSchema#string

Shawn R Makinen

http://www.w3.org/2001/XMLSchema#string

P2860

Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.

Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.

Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents.

Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents.

Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.

Toward improved immunocompetence of adoptively transferred CD8+ T cells

Adjuvants designed for veterinary and human vaccines.

Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.

Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies.

Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.

P304

453-461

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INTIMM/DXW017

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-04-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27055469

http://www.w3.org/2001/XMLSchema#string